Williams Joseph, Rosenquist Peter, Arias Lorraine, McCall W Vaughn
Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
J ECT. 2007 Sep;23(3):198-200. doi: 10.1097/YCT.0b013e318070c686.
Clinically significant pseudocholinesterase deficiency is a relatively uncommon disorder, but when present, it presents clinicians with challenges regarding medication administration. This is especially true in cases of patients receiving electroconvulsive therapy (ECT), as the presence of pseudocholinesterase deficiency limits the use of certain muscle relaxants. The authors describe a patient receiving ECT for treatment of his depression, who also possessed an unsuspected pseudocholinesterase deficiency. This was diagnosed after the patient was given succinylcholine, did not spontaneously recover motor function, and eventually required intubation. Subsequent ECT treatments were then managed with an alternative muscle relaxant which was not dependent on pseudocholinesterase for termination of action.
具有临床意义的假性胆碱酯酶缺乏是一种相对罕见的疾病,但一旦出现,会给临床医生在用药方面带来挑战。在接受电休克治疗(ECT)的患者中尤其如此,因为假性胆碱酯酶缺乏会限制某些肌肉松弛剂的使用。作者描述了一名因抑郁症接受ECT治疗的患者,该患者同时存在未被怀疑的假性胆碱酯酶缺乏。在给该患者使用琥珀酰胆碱后,其运动功能未自发恢复,最终需要插管,之后才诊断出假性胆碱酯酶缺乏。随后的ECT治疗改用了另一种肌肉松弛剂,该药物的作用终止不依赖于假性胆碱酯酶。